Streetbeat News

TSVT

2seventy bio, Inc.

https://www.2seventybio.com

Industry

Biotechnology

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Open

5.02

Mkt cap

254M

Volume

43K

High

5.04

P/E Ratio

-1.53

52-wk high

6.40

Low

4.88

Div yield

N/A

52-wk low

1.53

Novo Nordisk has acquired 2seventy Bio's Hemophilia A program and related gene editing technology. 2seventy Bio will now focus exclusively on its CAR T cell therapy, Abecma, in collaboration with Bristol Myers Squibb. The deal could bring up to $40 million to 2seventy Bio.

Portfolio Pulse from Vandana Singh

June 27, 2024 | 5:17 pm

Wedbush analyst David Nierengarten has reiterated a Neutral rating on 2seventy bio (NASDAQ:TSVT) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:41 pm

2seventy Bio shares are trading higher after the company announced the sale of its Hemophilia A candidate and MegaTAL to Novo Nordisk.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:12 pm

2seventy Bio has sold its Hemophilia A candidate and MegaTAL in vivo gene editing technology to Novo Nordisk for up to $40 million. This divestiture will allow 2seventy Bio to focus on the development and commercialization of Abecma.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:12 pm

Canaccord Genuity analyst John Newman maintains a Buy rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 7:08 pm

2seventy bio (NASDAQ:TSVT) reported Q1 adjusted losses of $(0.81) per share, aligning with analyst estimates, but saw a 25% improvement over last year's $(1.08) per share. However, their quarterly sales of $12.44M fell short of the expected $14.08M, marking an 11.68% miss and a significant 70.12% decrease from last year's $41.62M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:08 am

The FDA mandates boxed warnings for all CAR-T-based blood cancer therapies, including those by Bristol Myers Squibb, Johnson & Johnson, and others, due to risks of secondary cancers. Updates to labels and lifelong monitoring for secondary malignancies are required.

Portfolio Pulse from Vandana Singh

April 19, 2024 | 1:28 pm

The FDA has approved the use of a suspension lentiviral vector for the manufacturing of Abecma, as announced by 2Seventy Bio and Bristol Myers Squibb. This approval marks a significant advancement in the production process of Abecma.

Portfolio Pulse from Charles Gross

April 09, 2024 | 11:06 am

Citigroup analyst Samantha Semenkow maintains a Buy rating on 2seventy bio (NASDAQ:TSVT) and raises the price target from $9 to $12.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 10:12 pm

The FDA approved Bristol-Myers Squibb (BMY) and 2seventy Bio Inc's (TSVT) Abecma for earlier use in pretreated blood cancer patients, expanding its indication. The approval, based on the KarMMa-3 trial, shows Abecma extends progression-free survival in patients with relapsed or refractory multiple myeloma. The FDA also updated Abecma's boxed warning to include secondary cancer risks.

Portfolio Pulse from Vandana Singh

April 05, 2024 | 5:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.